Annual General Meeting 2017 in ChromoGenics AB (publ)
ChromoGenics AB (publ) held its Annual General Meeting May 10th 2017 in Uppsala.
Annual Report and Results
The Annual General Meeting adopted the profit and loss statement and the balance sheet for the financial year 2016 and decided, in accordance with the Board’s proposal, that the accumulated loss of a total of SEK 38,902,527 was carried forward in new account. It was further resolved that no dividend was to be paid.
The Annual General Meeting discharged the Board members and the Managing Director from liability for the financial year 2016.
Board and auditor’s fees
It was resolved to pay to each board member who is not i) employed by the company, ii) founder or main owner of the company, or iii) appointed by or a connected person to founder or main owner of the company, with SEK 100,000 for ordinary board members, and SEK 150,000 for the chairman. It was decided that remuneration to the auditor should be paid on an open account basis.
Election of Board and Auditor
As part of strengthening the company’s expertise, Peter Gustafson and Mari Broman were elected new directors of the Board. Anders Brännström, Claes-Göran Granqvist, Jerker Lundgren and Poul Erik Schou-Pedersen were re-elected as directors.
Decision on election committee
The Annual General Meeting resolved that the Company, in advance of the next general meeting to be held in 2018, shall establish a nomination committee. The chairman will instruct the three shareholders with the largest holdings of shares/votes in the Company to appoint a representative each that together with the chairman shall constitute the nomination committee.
Share issue authorization
The Annual General Meeting resolved to authorize the Board, on one or more occasions until the next annual general meeting, to issue shares, warrants and / or convertibles. with or without deviation from the shareholders’ pre-emption rights and/or an issue in kind, an issue by way of set-off or any other conditions. The authorization can be used to issue maximum 2 321 432 shares, which corresponds to approximately 10 per cent of the outstanding number of shares.
ChromoGenics AB (publ) Uppsala, May 10, 2017 The Board
Contact: Thomas Almesjö, CEO Susanne Andersson, CFO & Head of Communication Tel: +46 18 430 0430 E-mail: firstname.lastname@example.org
This information is such that ChromoGenics AB (publ) is obliged to make public pursuant to the Market Securities Act (2007:528) and/or to the Act (1991:980) regarding trading with financial instruments. The information was submitted for publication, through the agency of the contact person set out above, at 16:00 CET on May 10, 2017.Every care has been taken in the translation of this document. In the event of discrepancies, the Swedish original will supersede the English translation.
ChromoGenics is a leader in dynamic glass with controllable heat- and light transmission. The company’s unique electrochromic technology ConverLight™, provides sustainable solar control with increased indoor comfort and energy efficiency. In 2016 the company started commercial sales to real estate projects in Scandinavia.
ChromoGenics is located in Uppsala and has about 20 employees. The technology is derived from the world leading research center at Ångström Laboratory at Uppsala University. The plant has been partly financed by a conditional loan from the Swedish Energy Agency. ChromoGenics share (CHRO) is listed on Nasdaq First North Stockholm with G&W Fondkommission as Certified Adviser.